http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0858802-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2836f8341ba126b9578fbe852b71fab5
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-385
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
filingDate 1997-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05a859d81304bfce89a10af2fd181c75
publicationDate 2000-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-0858802-A3
titleOfInvention Pharmaceutical preparation of thioctic acid for oral administration
abstract (a) der Wirkstoffgehalt 70 bis 95 Gew.-%, bezogen auf dasnGesamtgewicht der Darreichungsform, beträgt, (b) mindestens 90 Gew.-% des Wirkstoffs eine Partikelgrößenkleiner als 200 µm aufweisen und (c) die Darreichungsform poröses amorphes Siliciumdioxidnin einer Menge von 0,2 bis 5 Gew.-%, bezogen auf dasnGesamtgewicht der Darreichungsform, und zum Rest pharmazeutischnannehmbare Hilfsstoffe enthält. A tablet-like dosage form for the active ingredient thioctic acid is described, which is characterized in that (a) the active ingredient content is 70 to 95% by weight, based on the total weight of the dosage form, (b) at least 90% by weight of the active ingredient have a particle size of less than 200 μm and (c) the dosage form contains porous amorphous silicon dioxide in an amount of 0.2 to 5% by weight, based on the total weight of the dosage form, and the remainder pharmaceutically acceptable excipients.
priorityDate 1997-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5376382-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1201014-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0659408-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0667155-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-4317646-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0702953-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0572922-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5455264-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0654484-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399223
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127822818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID50023
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547291
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136460
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129410028
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127401708
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226434370
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID864
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10215328
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6112
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128666532
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11645942
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5248
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127765137
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3024046
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129299315
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128361396

Total number of triples: 41.